Valuation: Vivesto AB

Market Cap 99.53M 10.5M 8.99M 8.39M 7.7M 14.47M 1B 14.75M 38.8M 504M 39.43M 38.58M 1.67B P/E 2026 *
-2.99x
P/E 2027 * -2.48x
Enterprise Value 91.53M 9.66M 8.27M 7.72M 7.08M 13.3M 924M 13.57M 35.68M 463M 36.27M 35.48M 1.53B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
52.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Vivesto AB

1 day-1.45%
1 week-1.45%
Current month+5.73%
1 month+0.68%
3 months+5.48%
6 months+2.19%
Current year-34.37%
1 week 8.5
Extreme 8.5
9.05
1 month 8.26
Extreme 8.26
9.14
Current year 7
Extreme 7
19.5
1 year 7
Extreme 7
27.3
3 years 7
Extreme 7
90.6
5 years 7
Extreme 7
302.9
10 years 7
Extreme 7
1,670
Manager TitleAgeSince
Chief Executive Officer 68 22/01/2023
Director of Finance/CFO 55 30/06/2026
Chief Tech/Sci/R&D Officer 39 31/12/2022
Director TitleAgeSince
Chairman 46 24/05/2022
Director/Board Member 61 25/09/2019
Director/Board Member 43 24/05/2022
Date Insider Type Main position Quantity % Market Cap.
25/03/22 Buy

Chief Executive Officer

12,200 0.0027%
24/03/22 Others

Chairman

120,000 0.0268%
20/12/21 Free

Chief Executive Officer

2,250,000 0.5018%
Change 5-day change 1-year change 3-year change Capi.($)
-1.45%-1.45%-63.24%-63.16% 10.53M
-1.62%+4.72%+79.46%+130.16% 1,141B
-1.22%+3.27%+51.34%+61.73% 659B
-0.48%+5.72%+26.78%+76.58% 470B
+1.20%+2.62%+41.69%+46.21% 366B
-0.61%+2.10%+23.43%+40.38% 302B
+0.32%+3.25%+0.94%+13.25% 254B
-1.65%+4.28%+46.98%+67.13% 239B
-1.10%-0.70%-14.31%-53.04% 207B
-1.49%+5.37%+22.60%+91.68% 183B
Average -0.84%+4.06%+21.57%+41.09% 382.1B
Weighted average by Cap. -0.92%+4.31%+45.04%+73.16%

Financials

2026 *2027 *
Net sales - -
Net income -31M -3.27M -2.8M -2.61M -2.4M -4.51M -313M -4.59M -12.08M -157M -12.28M -12.02M -519M -40M -4.22M -3.61M -3.37M -3.09M -5.81M -404M -5.93M -15.59M -202M -15.85M -15.5M -670M
Net Debt -8M -844K -723K -674K -619K -1.16M -80.77M -1.19M -3.12M -40.48M -3.17M -3.1M -134M -17M -1.79M -1.54M -1.43M -1.31M -2.47M -172M -2.52M -6.63M -86.02M -6.74M -6.59M -285M
Logo Vivesto AB
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Employees
4
Date Price Change Volume
20/08/26 SEK 8.860 -1.45% 6,741
19/08/26 SEK 8.990 -0.22% 13,445
18/08/26 SEK 9.010 +3.33% 43,456
17/08/26 SEK 8.720 -2.90% 10,595
14/08/26 SEK 8.980 -0.11% 1,575

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VIVE Stock